Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
It is a reason to monitor appropriately and reassess HRT necessity as body composition changes during tirzepatide treatment
Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
K., Lopez, L
Your health journey with GLP-1s is a marathon, not a sprint
US$ 23.87
US$ 20.80
US$ 24.26
US$ 21.02
US$ 22.47
US$ 21.75
